Werewolf Therapeutics (NASDAQ:HOWL) is a biotechnology firm dedicated to advancing a portfolio of innovative cancer treatments. Its focus includes the development of novel immunotherapies designed to awaken the body's immune system to recognize and destroy cancer cells more effectively. By leveraging its proprietary PREDATOR platform, Werewolf Therapeutics aims to engineer therapies that can modulate the tumor microenvironment, turning "cold" tumors "hot" and making them more susceptible to immune system attack. The company's objectives revolve around pushing the boundaries of cancer treatment through continuous research and development, aiming to transition promising laboratory findings into clinical trials where they can potentially improve patient outcomes. With a vision set on transforming cancer care, Werewolf Therapeutics is committed to pioneering the next generation of oncology therapies.